This study is about finding new treatments for a type of lung disease called pulmonary hypertension (PH), specifically a kind called Cpc-PH, which is related to heart problems. Researchers are using a medicine called sotatercept to see if it helps people with Cpc-PH caused by heart failure with preserved ejection fraction (HFpEF). People who were in a previous study (parent study) of sotatercept might qualify to join this extension study. The goal is to check if sotatercept is safe and works well when used for a longer time.

Key Points:

• This study is only for those who finished the earlier study (MK-7962-007, called CADENCE) without issues.
• It excludes those with certain types of PH, liver problems, or if they are pregnant or breastfeeding.
• Participants will be monitored for safety over a longer period with no mention of compensation.